Aytu BioPharma reports FY2026 revenue $57.6M and Q4 $16.1M
FY2026 net revenue fell to $57.6M from $66.4M, while Q4 net revenue rose to $16.1M (+6.4% YoY). Fourth-quarter Adjusted EBITDA was $0.5M; full-year Adjusted EBITDA was a loss.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.